AR021757A1 - METHOD FOR INHIBITING THE CONVERSION OF 4-ANDROSTAN-3,17-DIONA IN TESTOSTERONE OR 3ALFA-ANDROSTAN-3,17-DIONA IN DIHYDROTESTOSTERONE, INHIBIT THE ACTIVITY OF 3ALFA-HYDROXYSTEROID DEHYDROGENASE OF TYPE 3 OF HIFTIVA OF TYPE 3 PUTATIVE INHIBITOR OF THE CONVERSION OF 4-ANDROSTEN-3 - Google Patents

METHOD FOR INHIBITING THE CONVERSION OF 4-ANDROSTAN-3,17-DIONA IN TESTOSTERONE OR 3ALFA-ANDROSTAN-3,17-DIONA IN DIHYDROTESTOSTERONE, INHIBIT THE ACTIVITY OF 3ALFA-HYDROXYSTEROID DEHYDROGENASE OF TYPE 3 OF HIFTIVA OF TYPE 3 PUTATIVE INHIBITOR OF THE CONVERSION OF 4-ANDROSTEN-3

Info

Publication number
AR021757A1
AR021757A1 ARP990103961A ARP990103961A AR021757A1 AR 021757 A1 AR021757 A1 AR 021757A1 AR P990103961 A ARP990103961 A AR P990103961A AR P990103961 A ARP990103961 A AR P990103961A AR 021757 A1 AR021757 A1 AR 021757A1
Authority
AR
Argentina
Prior art keywords
group
type
hydrogen
androstan
alkyl
Prior art date
Application number
ARP990103961A
Other languages
Spanish (es)
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of AR021757A1 publication Critical patent/AR021757A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Abstract

Método para inhibir la conversion de 4-androstan-3,17-diona en testosterona o de 3alfa-androstan-3,17-diona en dihidrotestosterona en un paciente quenecesita dicha inhibicion que comprende la administracion a dicho paciente de una cantidad terapéuticamente efectiva de un inhibidor de la 3 alfa-hidroxiesteroide deshidrogenasa de tipo 3 humana. El inhibidor de la 3alfa-hidoxiesteroide deshidrogenasa de tipo 3 humana que posee la siguiente estructura: 1donde la línea de puntos es un enlace pi optativo; donde R3 es una porcion seleccionada del grupo formado por C1-20-alquiloxi, C1-10-aciloxi,C1-20-alcoxicarboniloxi, C1-20-alquiloxialquiloxi, hidroxilo, (N-alquil o -H)-carbamato y un grupo transformado in vivo en hidroxilo; donde R2 y R4 seseleccionan independientemente del grupo formado por hidrogeno, ciano, fluoro, cloro, bromo y nitro (donde R2 y R4 no son hidrogeno simultáneamente); dondeR17alfa se selecciona del grupo formado por hidogeno, una porcion carbonada de C2-14 sustituida porun radical seleccionado del grupo formado por hidrogeno,halogeno, carboxilo, amida, C1-3-alcoxi, C1-3-alquilo y fenilo sustituido con R100, donde R100 se selecciona del grupo formado por hidrogeno, carboxilo, amida,C1-5-alquilo, halo, nitro, hidroxilo y C1-3-alcoxi; o R17alfa y R18beta forman juntos un anillo C5-7-lactona o es un oxígeno cetonico; donde R17beta eshidroxilo, aciloxi, alcoxi, alqueniloxi, (N-alquil o H); o R17alfa y R17beta forman juntos un anillo C5-7-lactona o es un oxígeno cetonico; donde R16alfa yR16beta se seleccionan independientemente del grupo formado por hidrogeno, alquilo inferior y bencilo; o R16alfa y R16beta forman juntos a C5-6-cicloalqueno.Método de tratamiento y/o inhibicion del desarrollo del cáncer de prostata, hiperplasia prostática benigna, prostatitis,a cné, seborrea, hirsutismo o alopecíaandrogénica en los que se utilizan inhibidores de la 3-alfa hidroxiesteroide deshidrogenasa de tipo 3, solos o en combinacion con otros fármacos activos talescomo los inhibidores de la 17beta-deshidrogenasa de tipo 5. Un inhibidor de la 3alfa-hidroxiesteroide deshidrogenasa de tipo 5. Un inhibidor de la 3alfaMethod for inhibiting the conversion of 4-androstan-3,17-dione in testosterone or 3alpha-androstan-3,17-dione in dihydrotestosterone in a patient who needs said inhibition comprising the administration to said patient of a therapeutically effective amount of a human type 3 alpha-hydroxysteroid dehydrogenase inhibitor. The human type 3 3-alpha-hidoxysteroid dehydrogenase inhibitor that has the following structure: 1 where the dotted line is an optional pi bond; where R3 is a portion selected from the group consisting of C1-20-alkyloxy, C1-10-acyloxy, C1-20-alkoxycarbonyloxy, C1-20-alkyloxyalkyloxy, hydroxy, (N-alkyl or -H) -carbamate and a transformed group in vivo in hydroxyl; where R2 and R4 are independently selected from the group consisting of hydrogen, cyano, fluoro, chloro, bromo and nitro (where R2 and R4 are not hydrogen simultaneously); where R17alpha is selected from the group consisting of hydrogen, a carbonized portion of C2-14 substituted by a radical selected from the group consisting of hydrogen, halogen, carboxyl, amide, C1-3-alkoxy, C1-3-alkyl and phenyl substituted with R100, where R100 is selected from the group consisting of hydrogen, carboxyl, amide, C1-5-alkyl, halo, nitro, hydroxyl and C1-3-alkoxy; or R17alfa and R18beta together form a C5-7-lactone ring or is a ketone oxygen; where R17beta is hydroxy, acyloxy, alkoxy, alkenyloxy, (N-alkyl or H); or R17alfa and R17beta together form a C5-7-lactone ring or is a ketone oxygen; where R16alfa and R16beta are independently selected from the group consisting of hydrogen, lower alkyl and benzyl; or R16alfa and R16beta together form C5-6-cycloalkene. Method of treatment and / or inhibition of the development of prostate cancer, benign prostatic hyperplasia, prostatitis, cne, seborrhea, hirsutism or androgenic alopecia in which inhibitors of 3 -alpha hydroxysteroid dehydrogenase type 3, alone or in combination with other active drugs such as inhibitors of 17beta-dehydrogenase type 5. An inhibitor of 3alpha-hydroxysteroid dehydrogenase type 5. An inhibitor of 3alpha

ARP990103961A 1998-08-07 1999-08-06 METHOD FOR INHIBITING THE CONVERSION OF 4-ANDROSTAN-3,17-DIONA IN TESTOSTERONE OR 3ALFA-ANDROSTAN-3,17-DIONA IN DIHYDROTESTOSTERONE, INHIBIT THE ACTIVITY OF 3ALFA-HYDROXYSTEROID DEHYDROGENASE OF TYPE 3 OF HIFTIVA OF TYPE 3 PUTATIVE INHIBITOR OF THE CONVERSION OF 4-ANDROSTEN-3 AR021757A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9562398P 1998-08-07 1998-08-07

Publications (1)

Publication Number Publication Date
AR021757A1 true AR021757A1 (en) 2002-08-07

Family

ID=22252842

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103961A AR021757A1 (en) 1998-08-07 1999-08-06 METHOD FOR INHIBITING THE CONVERSION OF 4-ANDROSTAN-3,17-DIONA IN TESTOSTERONE OR 3ALFA-ANDROSTAN-3,17-DIONA IN DIHYDROTESTOSTERONE, INHIBIT THE ACTIVITY OF 3ALFA-HYDROXYSTEROID DEHYDROGENASE OF TYPE 3 OF HIFTIVA OF TYPE 3 PUTATIVE INHIBITOR OF THE CONVERSION OF 4-ANDROSTEN-3

Country Status (9)

Country Link
EP (1) EP1102582A2 (en)
JP (1) JP2002522380A (en)
CN (1) CN1322130A (en)
AR (1) AR021757A1 (en)
AU (1) AU5144999A (en)
CA (1) CA2339368A1 (en)
ID (1) ID28791A (en)
NO (1) NO20010651L (en)
WO (1) WO2000007576A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
EP1321146A3 (en) * 1998-03-11 2004-06-02 Endorecherche Inc. Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6891953B1 (en) 2000-06-27 2005-05-10 Microsoft Corporation Method and system for binding enhanced software features to a persona
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
CA2430100A1 (en) * 2000-11-27 2002-05-30 Entremed, Inc. Antiangiogenic agents
US6710037B2 (en) * 2001-05-01 2004-03-23 Schering Corporation Method of treating androgen-dependent disorders
CA2458452C (en) * 2001-08-10 2011-04-19 Takeda Chemical Industries, Ltd. Gnrh agonist combination drugs
ES2305350T3 (en) * 2001-11-29 2008-11-01 Gtx, Inc. PREVENTION AND TREATMENT OF OSTEOPOROSIS INDUCED BY THE PRIVACY OF ANDROGENS.
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
CA2558014A1 (en) 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
US7419972B2 (en) 2004-07-02 2008-09-02 Schering Ag 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
DE102004032674A1 (en) * 2004-07-02 2006-01-26 Schering Ag New 2-substituted Estra-1,3,5 (10) -triene-17-ones as inhibitors of 17β-hydroxysteroid dehydrogenase type 1
JP2009530388A (en) 2006-03-20 2009-08-27 エントレメッド インコーポレイテッド Disease-modifying anti-arthritic activity of 2-methoxyestradiol
US9284345B2 (en) * 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
MX2010002268A (en) * 2007-08-31 2010-03-25 Astellas Pharma Inc Piperidine derivative.
CN101698834B (en) * 2009-09-08 2012-05-23 北京利德曼生化股份有限公司 3 alpha-hydroxysteroid dehydrogenase, nucleotide sequence thereof, recombinant vector thereof, recombinant host cells thereof and kit
BR112015000443A2 (en) 2012-07-10 2017-06-27 Bayer Pharma AG 3-substituted estra-1,3,5 (10), 16-tetraene derivatives, process for their manufacture, pharmaceutical preparations containing them, as well as their use for the production of medicaments
CN105008382B (en) 2013-02-21 2018-01-30 拜耳医药股份公司 For suppressing the female steroid 1,3,5 (10) of 17 11-beta-hydroxysteroid dehydrogenase types (AKR1 C3), the carboxylic acid amides of 16 tetraene 3
CN104873520A (en) * 2014-02-27 2015-09-02 天津药物研究院 11 beta-hydroxysteroid dehydrogenase inhibitor and its pharmaceutical composition and use
CN104873525A (en) * 2014-02-27 2015-09-02 天津药物研究院 11 beta-hydroxysteroid dehydrogenase inhibitor and its pharmaceutical composition and use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562260A (en) * 1965-08-23 1971-02-09 Ormonoterapia Richter Spa 2-carbonyl-estratrienes and method of their preparation
US4340602A (en) * 1978-10-18 1982-07-20 Wayne State University Compositions inhibiting estrogen sulfotransferase activity
IT1174487B (en) * 1983-02-22 1987-07-01 Joachim Georg Liehr BETTER IN OR RELATING TO THE TREATMENT OF THE CONDITIONS OF INSUFFICIENCY OF ESTROGENS
US4568673A (en) * 1984-03-20 1986-02-04 Wayne State University Compositions inhibiting murine MXT ductal carcinoma
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
CA2323089A1 (en) * 1998-03-11 1999-09-16 Endorecherche, Inc. Inhibitors of type 5 and type 3 17.beta.-hydroxysteroid dehydrogenase and methods for their use

Also Published As

Publication number Publication date
CN1322130A (en) 2001-11-14
AU5144999A (en) 2000-02-28
WO2000007576A3 (en) 2000-03-30
NO20010651L (en) 2001-04-05
CA2339368A1 (en) 2000-02-17
ID28791A (en) 2001-07-05
NO20010651D0 (en) 2001-02-07
WO2000007576A2 (en) 2000-02-17
EP1102582A2 (en) 2001-05-30
JP2002522380A (en) 2002-07-23

Similar Documents

Publication Publication Date Title
AR021757A1 (en) METHOD FOR INHIBITING THE CONVERSION OF 4-ANDROSTAN-3,17-DIONA IN TESTOSTERONE OR 3ALFA-ANDROSTAN-3,17-DIONA IN DIHYDROTESTOSTERONE, INHIBIT THE ACTIVITY OF 3ALFA-HYDROXYSTEROID DEHYDROGENASE OF TYPE 3 OF HIFTIVA OF TYPE 3 PUTATIVE INHIBITOR OF THE CONVERSION OF 4-ANDROSTEN-3
BRPI0506470A (en) helix-directed steroidal pharmaceuticals 12, including molecular compound of the formula or salt thereof; pharmaceutical composition and treatment method
BRPI0307699A2 (en) Treatment of benign prostatic hyperplasia with sarms.
PE15095A1 (en) DERIVATIVE OF ANDROSTENONE
RS20070489A (en) Helix 12 directed non-steroidal antiandrogens
HUT60139A (en) Process for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen
BR9908592A (en) Process for inhibiting the activity of 17ß-hydroxysteroid dehydrogenase type 5, pharmaceutical composition, 17ß-hydroxysteroid dehydrogenase type 5 inhibitor, process for inhibiting 17ß-hydroxysteroid dehydrogenase type 3, 17ß-hydroxysteroid dehydrogenase type 3, processes to treat, or reduce the risk of developing, prostate cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism or androgenic alopecia, polycystic ovary syndrome, breast cancer, endometriosis or leiomyoma, to inhibit testicular hormone secretions, to treat early puberty, and, kit
AR012660A1 (en) USE OF QUINAZOLINE COMPOUNDS FOR THE MANUFACTURE OF A MEDICINE USEFUL FOR THE TREATMENT OF POLYCHYSTIC DISEASES OF THE KIDNEY.
KR910004651A (en) 17β-acyl-4-aza-5α-androst-1-en-3-one as a 5α-reductase inhibitor
PL338885A1 (en) Combination of thyrisinic kinase inhibitor and pharmacological castration for treating prostatic carcinoma
DE69125714D1 (en) COMPOSITION FOR THE TREATMENT OF HUMAN PROSTATE ADENOCARCINOMA
MY131522A (en) PHARMACEUTICAL COMPOSITION AND USES FOR ANDROST-5-ENE-3ß,17ß-DIOL
Sun et al. A review on steroidal 5α-reductase inhibitors for treatment of benign prostatic hyperplasia
Di Salle et al. PNU 157706, a novel dual type I and II5α-reductase inhibitor
WO2001017479A3 (en) Methods and compositions for preventing and treating prostate disorders
WO2001022919A3 (en) Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and uses thereof
Frye Inhibitors of 50a-Reductase
JPH07508290A (en) 17α and 17β substituted acyl 4 azasteroids
NZ327041A (en) 17-beta-cyclopropyl(amino/oxy) 4-aza steriods as active inhibitors of testosterone 5-alpha-reductase and C17-20-lyase
US20010028897A1 (en) Compositions and treatment methods for benign prostatic hypertrophy
RU95110751A (en) NEW 17β-SUBSTITUTED DERIVATIVES OF 4-AZAANDROSTANE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF AND METHOD OF THEIR PREPARING
ES2149984T3 (en) IMIDAZOLY ALKYL DERIVATIVES OF IMIDAZOL (5,1-C) (1,4) BENZOXAZIN-1-ONA AND ITS USE AS THERAPEUTIC AGENTS.
Garg et al. Management of benign prostate hyperplasia: An overview of α-adrenergic antagonist
US20060154909A1 (en) 1,4,6-androstatriene-3,17-dione ("ATD") for therapeutic uses
Sunde et al. Effects in vitro of medroxyprogesterone acetate on steroid metabolizing enzymes in the rat: selective inhibition of 3α-hydroxysteroid oxidoreductase activity